Prognostic value of a novel scoring system using inflammatory response biomarkers in non-small cell lung cancer: A retrospective study

Yan Wang1*, Xu Hu2*, Wenying Xu3, Haoyuan Wang3, Yu Huang3 & Guowei Che1

1 Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China
2 West China School of Medicine, Sichuan University, Chengdu, China

Keywords
Inflammatory response biomarker score; lymphocyte-to-monocyte ratio; neutrophil-to-lymphocyte ratio; platelet-to-lymphocyte ratio; non-small cell lung cancer.

Correspondence
Guowei Che, Department of Thoracic Surgery, West China Hospital, Sichuan University, Guoxuexiang No. 37, Chengdu, China. Tel: +86 28 189 8060 (ext. 1890) Fax: +86 28 8542 2494 Email: hx_guowei_che@foxmail.com

*Yan Wang and Xu Hu contributed equally.

Received: 26 February 2019; Accepted: 19 April 2019.

doi: 10.1111/1759-7714.13085
Thoracic Cancer 10 (2019) 1402–1411

Abstract

Background: The neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) are reported to show a strong correlation with prognosis in patients with non-small cell lung cancer (NSCLC). We aimed to describe a novel scoring system combining these ratios, termed the inflammatory response biomarker (IRB) score, and test its prognostic value in NSCLC.

Methods: The data of 261 NSCLC patients who underwent thoracoscopic radical resection in a single center were retrospectively reviewed. The IRB score was defined as follows: a high NLR (> 2.12), a high PLR (92.9), and a low LMR (< 4.57) were each scored as 1; the opposite values were scored as 0. The individual scores were added to produce the IRB score (range: 0–3).

Results: Multivariate analyses indicated that high tumor node metastasis (TNM) stage (hazard ratio [HR] 2.721, 95% confidence interval [CI] 1.597–4.989; \( P < 0.001 \)) and an IRB score ≥ 2 (HR 2.696, 95% CI 1.506–4.826; \( P = 0.001 \)) were independent prognostic factors for poor overall survival. Furthermore, smoking history (HR 2.953, 95% CI 1.086–8.026; \( P = 0.034 \)), high TNM stage (HR 3.108, 95% CI 1.911–5.056; \( P < 0.001 \)), and IRB score ≥ 2 (HR = 2.316, 95% CI: 1.389–3.861; \( P = 0.001 \)) were demonstrated to be independent prognostic factors for poor disease-free survival.

Conclusion: The novel scoring system combining NLR, PLR, and LMR was an independent prognostic factor in NSCLC patients undergoing thoracoscopic radical resection and was superior to these ratios alone for predicting prognosis.

Introduction

Lung cancer is the leading cause of cancer death worldwide and non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers.1,2 Despite great advances in methods of diagnosis, treatment and follow-up, the prognosis of lung cancer remains unsatisfactory as a result of local tumor recurrence and distant metastasis in China,3 the median survival duration of lung cancer patients is only 22.7 months.4 Therefore, efficient and reliable prognostic factors that could guide clinicians to develop the most appropriate therapeutic strategies are urgently needed.

Previous studies have revealed that age, gender, smoking, and tumor node metastasis (TNM) stage are reliable prognostic markers for lung cancer.5–8 Nevertheless, patients at the same TNM stage may still have different clinical outcomes.9 There are also some novel biomarkers that are significantly associated with the survival of lung cancer patients and can effectively guide clinical treatments, such as EGFR and IDM-1.10,11 However, these markers are costly and time-consuming to measure. Therefore, there are currently no valuable prognostic factors that can be easily obtained to precisely predict the survival of lung cancer patients.

In recent years, the systemic inflammatory response (SIR) has been proven to play a key role in cancer progression, development, and metastasis.12 The neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio...
(PLR), and lymphocyte-to-monocyte ratio (LMR) are good markers of the SIR and have shown a significant correlation with clinical outcomes in multiple tumors. In particular, they are simple to derive and economical. However, almost all studies on these factors only focused on a single indicator and their results were inconsistent. Therefore, we hypothesized that a scoring system combining these ratios may possess higher prognostic value than a single ratio.

In the current study, we described a novel prognostic scoring system using the NLR, PLR, and LMR that we termed the inflammatory response biomarker (IRB) score, and evaluated its prognostic significance in NSCLC patients undergoing thoracoscopic radical resection.

**Methods**

**Study design**

This is a retrospective study from a single center. All procedures performed involving human participants were conducted in accordance with the standards of the Ethics Committee of West China Hospital, Sichuan University and National Research Committee, and the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Because of the retrospective design of the study, informed consent was not required.

**Study population**

The data of patients diagnosed with NSCLC in the same medical group at the Department of Thoracic Surgery, West China Hospital, between 1 January 2014 and 29 February 2016 were reviewed. NSCLC diagnoses were made pathologically with bronchoscopic biopsies, computed tomography-guided needle specimens, or surgically resected specimens. The inclusion criteria were as follows:

(i) pathologically confirmed NSCLC; (ii) patient underwent thoracoscopic radical lung resection and lymph node dissection; and (iii) blood tests were taken within one week preoperatively. The exclusion criteria were as follows:

(i) patient received neoadjuvant therapy; (ii) clinical evidence of preoperative inflammatory condition or infection, such as inflammatory bowel disease or rheumatoid arthritis; (iii) other malignancies present; (iv) recurrent tumors; (v) patient underwent another surgery within three months before thoracoscopic radical resection; (vi) surgery was altered to thoracotomy; and (vii) insufficient data.

**Data collection**

All clinicopathological data was extracted from electronic medical records, including gender, age, smoking history, preoperative comorbidity, preoperative lung function represented by forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and FEV1/FVC, size, pathology, extent of resection, TNM stage (based on the 7th Union for International Cancer Control TNM classification), and laboratory data.

**Calculation and definition of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) and inflammatory response biomarker (IRB) score**

The NLR was defined as a simple ratio between the absolute neutrophil and lymphocyte counts. The PLR was defined as a simple ratio between the absolute platelet and lymphocyte counts. The LMR was defined as a simple ratio between the absolute lymphocyte and monocyte counts.

The optimal NLR, PLR, and LMR cutoff values for predicting death were determined by receiver operating curve (ROC) analysis. For the NLR, the cutoff value and the area under the curve (AUC) were 2.12 and 0.672, respectively, with a sensitivity of 60.0% and a specificity of 58.7%. For the PLR, the cutoff value and the AUC were 92.9 and 0.715, respectively, with a sensitivity of 67.7% and a specificity of 53.1%. For the LMR, the cutoff value and the AUC were 4.57 and 0.679, respectively, with a sensitivity of 69.2% and a specificity of 56.6%.

The IRB score was defined as follows: a high NLR (> 2.12), a high PLR (> 92.9) and a low LMR (< 4.57) were each scored as 1; the opposite values were scored as 0. The individual scores were added to determine the IRB score (range: 0–3).

**Follow-up and the endpoint event**

Follow-up information was obtained via telephone or directly from outpatient clinic records. The primary endpoint events of the current study were overall survival (OS) and disease-free survival (DFS). OS was defined as the interval from the date of surgery to the date of death from any cause or the last visit, and DFS was defined as the interval from the date of surgery to the date of recurrence, metastasis, or last follow-up. Patients known to be alive at the last follow-up were censored.

**Statistical analysis**

We used Microsoft Office Excel 2007 for data collection and SPSS version 22.0 for statistical analysis. Continuous and categorical variables were presented as median (range) values and numbers of patients (%), respectively. Student’s t-test or one-way analysis of variance were used to
compare continuous variables and \( \chi^2 \) or Fisher’s exact tests for comparison of categorical variables. The OS was calculated via Kaplan–Meier analysis and the differences between groups were assessed via the log-rank test. Prognostic factors for decreased OS rates were identified via the Cox regression model.

Univariate regression analyses were used to identify potential risk factors from the variables that seemed to be associated with prognosis based on clinical knowledge and previous studies; variables with a \( P \) value < 0.10 were included into multivariate regression analyses. To avoid the effect of NLR, PLR, and LMR on the IRB score in the Cox regression model, two models excluding and including the IRB score were constructed.

All statistical tests were two-sided and \( P \) values < 0.05 were considered statistically significant.

Results

Patients characteristics

We enrolled 261 patients into our analysis based on the inclusion and exclusion criteria. The patient screening process is shown in Figure 1. The median follow-up was 38 (range: 1–56) months. Among the 261 NSCLC patients, 144 (55.17%) were male and 123 (47.13%) were current or ex-smokers. Regarding preoperative comorbidities, 130 (49.81%) patients had at least one kind of comorbidity, including hypertension, diabetes mellitus, chronic obstructive pulmonary disease, coronary heart disease, and emphysema. Regarding the pathological type, 190 (72.80%) cases were adenocarcinomas, which accounted for the majority of the sample population. One hundred ninety (72.80%) patients underwent lobectomy and 134 (51.34%), 80 (30.65%), and 47 (18.01%) patients were in TNM stages I, II, and III, respectively. Detailed information is shown in Table 1.

Associations between the NLR, PLR, and LMR and clinicopathologic characteristics

After grouping the 261 patients according to the optimal cutoff values of NLR, PLR and LMR, we explored the associations between these ratios and patient characteristics. The NLR was significantly correlated with gender \( (P = 0.007) \), age \( (P = 0.017) \), smoking history \( (P = 0.002) \), preoperative hypertension \( (P = 0.038) \), tumor size \( (P = 0.044) \), pathology \( (P = 0.015) \), TNM stage \( (P = 0.001) \), PLR \( (P < 0.001) \), and LMR \( (P < 0.001) \). The PLR was significantly correlated with preoperative diabetes mellitus \( (P = 0.027) \), tumor size \( (P = 0.005) \), neutrophil count \( (P < 0.001) \), monocyte count \( (P = 0.034) \), NLR \( (P < 0.001) \), and LMR \( (P < 0.001) \). The LMR was significantly correlated with gender \( (P = 0.001) \), age \( (P = 0.007) \), smoking history \( (P < 0.001) \), preoperative emphysema \( (P = 0.013) \), preoperative FEV1/FVC \( (P = 0.004) \), tumor size \( (P = 0.037) \), TNM stage \( (P = 0.039) \), neutrophil count \( (P = 0.006) \), NLR \( (P < 0.001) \), and PLR \( (P < 0.001) \). It is notable that these three ratios were significantly associated...
Associations between the IRB score and clinicopathological characteristics

The IRB score was significantly correlated with the gender \((P = 0.002)\), age \((P = 0.024)\), smoking history \((P = 0.001)\), preoperative hypertension \((P = 0.018)\), preoperative emphysema \((P = 0.042)\), preoperative FEV1/FVC \((P = 0.005)\), tumor size \((P = 0.004)\), extent of resection \((P = 0.046)\), TNM stage \((P = 0.009)\), neutrophil count \((P < 0.001)\), platelet count \((P = 0.007)\), monocyte count \((P < 0.001)\), lymphocyte count \((P < 0.001)\), NLR \((P < 0.001)\), PLR \((P < 0.001)\), and LMR \((P < 0.001)\). Specific data is shown in Table 3.

Postoperative overall survival (OS) and disease-free survival (DFS) based on IRB score

During the follow-up period, the mean survival time of the 65 patients who died was 30.74 months, while the mean survival time of the 196 patients who were still alive was 41.78 months. The mean time to recurrence in 77 patients who experienced recurrence was 25.34 months compared to 41 months in 184 non-recurrent patients. Patients with an IRB score \(\leq 1\) had significantly improved OS \((P < 0.001)\) (Fig 2) and DFS \((P < 0.001)\) (Fig 3) compared to patients with an IRB score \(\geq 2\).

Prognostic factors of OS and DFS

Univariate analyses of OS revealed that the male gender (hazard ratio [HR] 1.689, 95% confidence interval [CI] 1.019–2.829; \(P = 0.042\)), age (HR 1.025, 95% CI 0.995–1.056; \(P = 0.098\)), smoking history (HR 2.272, 95% CI 1.370–3.768; \(P = 0.001\)), preoperative emphysema (HR 2.187, 95% CI 1.251–3.822; \(P = 0.006\)), larger tumors (HR 1.218, 95% CI 1.053–1.409; \(P = 0.008\)), high TNM stage (HR 1.926, 95% CI 1.236–3.338; \(P < 0.001\)), NLR \(\geq 2\) (HR 2.272, 95% CI 1.370–3.768; \(P = 0.005\)), PLR \(\geq 92.9\) (HR 2.064, 95% CI 1.234–3.451; \(P = 0.006\)), LMR \(\leq 4.57\) (HR 3.067, 95% CI 1.801–5.223; \(P < 0.001\)), and IRB score \(\geq 2\) (HR 3.579, 95% CI 2.052–6.241; \(P < 0.001\)) were potential risk factors for poor OS. In multivariate analyses, high TNM stage (HR 2.721, 95% CI 1.597–4.989; \(P < 0.001\)) and IRB score \(\geq 2\) (HR 2.696, 95% CI 1.506–4.826; \(P = 0.001\)) were independently associated with poorer OS (Table 4).

Univariate analyses of DFS showed that gender (HR 1.622, 95% CI 1.015–2.590; \(P = 0.043\)), smoking history (HR 2.001, 95% CI 1.265–3.165; \(P = 0.003\)), preoperative emphysema (HR 1.890, 95% CI 1.125–3.176; \(P = 0.016\)), FEV1/FVC (HR 0.234, 95% CI 0.046–1.196; \(P = 0.081\)), larger tumors (HR 1.230, 95% CI 1.077–1.406; \(P = 0.002\)), high TNM stage (HR 2.772, 95% CI 2.196–3.500; \(P < 0.001\)), NLR \(\geq 2.12\) (HR 2.451, 95% CI 1.597–4.989; \(P < 0.001\)), PLR \(\geq 92.9\) (HR 2.451, 95% CI 1.597–4.989; \(P < 0.001\)), and IRB score \(\geq 2\) (HR 2.696, 95% CI 1.506–4.826; \(P = 0.001\)) were independently associated with poor DFS (Table 5).

Discussion

In our study, we evaluated associations among NLR, PLR, LMR, and IRB scores with OS and DFS in NSCLC patients who underwent thoracoscopic radical resection. The main finding was that the IRB score was an independent prognostic factor in NSCLC patients and was superior to NLR, PLR, and LMR alone for predicting prognosis.

Over the past decade, numerous studies have shown a correlation between the SIR and several types of solid cancers, including lung cancer. Previous research demonstrated that the SIR could influence tumor progression by regulating the invasive and metastatic potential of lung cancer cells.

| Characteristics | N (%) |
|-----------------|-------|
| Male            | 144 (55.17) |
| Smoking history | 123 (47.13) |
| Preoperative comorbidity | |
| Hypertension    | 79 (30.27) |
| Diabetes mellitus | 26 (9.96) |
| COPD            | 39 (14.94) |
| CHD             | 12 (4.6)   |
| Emphysema       | 43 (16.48) |
| Any             | 130 (49.81) |
| Pathology       | |
| AC              | 190 (72.8) |
| SC              | 46 (17.62) |
| Others          | 25 (9.58)  |
| Extent of resection | |
| Lobectomy       | 190 (72.8) |
| Segmentectomy   | 71 (27.2)  |
| TNM stage       | |
| I               | 134 (51.34) |
| II              | 80 (30.65)  |
| III             | 47 (18.01)  |

AC, adenocarcinoma; COPD, chronic obstructive pulmonary disease; CHD, coronary heart disease; SC, squamous carcinoma; TNM, tumor node metastasis.
Table 2. Associations between the NLR, PLR, and LMR and clinicopathologic characteristics

| Characteristics | NLR < 2.12 (n = 141) | NLR ≥ 2.12 (n = 120) | P | PLR < 4.57 (n = 131) | PLR ≥ 4.57 (n = 130) | P | LMR < 92.92 (n = 134) | LMR ≥ 92.92 (n = 127) | P |
|-----------------|----------------------|-----------------------|---|-----------------------|-----------------------|---|-----------------------|-----------------------|---|
| **Male, N (%)** | 67 (47.52)           | 77 (64.17)            | 0.007 | 62 (49.61)           | 63 (53.87)            | 0.47 | 54 (43.52)           | 69 (59.82)            | 0.001 |
| **Age, median (range), year** | 62 (38-77) | 64 (41-81) | 0.78 | 62 (38-77) | 63 (39-81) | 0.147 | 59 (58-77) | 61 (38-77) | 0.15 |
| **Smoking history, N (%)** | 35 (24.82) | 35 (26.67) | 0.664 | 35 (26.67) | 35 (26.67) | 0.664 | 35 (26.67) | 35 (26.67) | 0.664 |
| **Preoperative comorbidity, N (%)** | 35 (24.82) | 35 (26.67) | 0.664 | 35 (26.67) | 35 (26.67) | 0.664 | 35 (26.67) | 35 (26.67) | 0.664 |
| **Preoperative lung function** | 2.20 (1.26-4.2) | 2.19 (1.96-4.5) | 0.527 | 2.19 (1.96-4.5) | 2.19 (1.96-4.5) | 0.527 | 2.19 (1.96-4.5) | 2.19 (1.96-4.5) | 0.527 |
| **Pathology (AC), N (%)** | 110 (78.01) | 80 (66.67) | 0.015 | 80 (66.67) | 80 (66.67) | 0.015 | 110 (78.01) | 80 (66.67) | 0.015 |
| **Resection (lobectomy), N (%)** | 98 (69.5) | 92 (76.67) | 0.195 | 98 (69.5) | 92 (76.67) | 0.195 | 98 (69.5) | 92 (76.67) | 0.195 |
| **TNM stage (I-II), N (%)** | 126 (89.36) | 112 (93.33) | 0.059 | 110 (86.61) | 104 (77.61) | 0.059 | 126 (89.36) | 112 (93.33) | 0.059 |
| **FEV1, median (range), L** | 2.20 (1.26-4.2) | 2.19 (1.96-4.5) | 0.527 | 2.19 (1.96-4.5) | 2.19 (1.96-4.5) | 0.527 | 2.19 (1.96-4.5) | 2.19 (1.96-4.5) | 0.527 |
| **FVC, median (range), L** | 2.20 (1.26-4.2) | 2.19 (1.96-4.5) | 0.527 | 2.19 (1.96-4.5) | 2.19 (1.96-4.5) | 0.527 | 2.19 (1.96-4.5) | 2.19 (1.96-4.5) | 0.527 |
| **FEV1/FVC, median** | 2.20 (1.26-4.2) | 2.19 (1.96-4.5) | 0.527 | 2.19 (1.96-4.5) | 2.19 (1.96-4.5) | 0.527 | 2.19 (1.96-4.5) | 2.19 (1.96-4.5) | 0.527 |
| **Tumor size, median (range), cm** | 2.20 (1.26-4.2) | 2.19 (1.96-4.5) | 0.527 | 2.19 (1.96-4.5) | 2.19 (1.96-4.5) | 0.527 | 2.19 (1.96-4.5) | 2.19 (1.96-4.5) | 0.527 |

Bold text indicates significance. AC, adenocarcinoma; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; LMR, lymphocyte-to-monocyte ratio; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; SC, squamous carcinoma; SD, standard deviation; TNM, tumor node metastases.
there are also many biomarkers that could represent systemic inflammation well. Unfortunately, some of these are not clinically accessible or are only applied as research tools, such as the modified Glasgow prognostic score (mGPS, a composite score derived from albumin levels and CRP). A blood test is easy to obtain and is inexpensive, and almost every patient undergoes this test before surgery. Therefore, it would be very helpful for clinicians to develop and adjust treatment

Table 3 Associations between the IRB score and clinicopathological characteristics

| Characteristics                        | IRB score |                |                |
|---------------------------------------|-----------|----------------|----------------|
|                                       | < 2 (n = 128) | ≥ 2 (n = 133) | P              |
| Male, N (%)                           | 58 (45.31) | 86 (64.66)     | 0.002          |
| Age, median (range), year             | 62 (38–77) | 64 (41–81)     | 0.024          |
| Smoking history, N                    | 47 (36.72) | 76 (57.14)     | 0.001          |
| Preoperative comorbidity, N (%)       |           |                |                |
| Hypertension                          | 30 (23.44) | 49 (36.84)     | 0.018          |
| Diabetes mellitus                     | 13 (10.16) | 13 (9.77)      | 0.918          |
| COPD                                  | 17 (13.28) | 22 (16.54)     | 0.46           |
| CHD                                   | 6 (4.69)   | 6 (4.51)       | 0.946          |
| Emphysema                             | 15 (11.72) | 28 (21.05)     | 0.042          |
| Preoperative lung function            |           |                |                |
| FEV1, median (range), L               | 2.22 (0.76–4.2) | 2.18 (0.92–4.55) | 0.382 |
| FVC, median (range), L                | 2.97 (1.35–5.8) | 3.1 (1.06–5.72) | 0.588 |
| FEV1/FVC, %                           | 78.05 (38.91–90.4) | 75 (36.8–96.49) | 0.005 |
| Tumor size, median (range), cm        | 2.2 (0.5–7) | 2.6 (0.6–7)    | 0.004          |
| Pathology (AC), N (%)                 | 98 (76.56) | 92 (69.17)     | 0.095          |
| Rejection (lobectomy), n (%)          | 86 (67.19) | 104 (78.20)    | 0.046          |
| TNM stage (I–II), N (%)               | 113 (88.28) | 101 (75.94)    | 0.009          |
| Neutrophil count, median (range), 10^9/L | 3.17 (1.32–8.26) | 3.94 (1.73–12.68) | <0.001 |
| Platelet count, median (range), 10^9/L | 156.5 (70–337) | 181 (73–391)   | 0.007          |
| Monocyte count, median (range), 10^9/L | 0.36 (0.08–0.86) | 0.42 (0.1–1.26) | <0.001 |
| Lymphocyte count, median (range), 10^9/L | 2 (0.98–4.32) | 1.46 (0.56–2.55) | <0.001 |
| NLR, median (range), %                | 1.61 (0.7–5.1) | 2.78 (1.17–20.45) | <0.001 |
| PLR, median (range), %                | 80.87 (35.9–167.28) | 122.41 (39.48–323.33) | <0.001 |
| LMR, median (range), %                | 5.69 (2.6–15.57) | 3.53 (0.89–10.73) | <0.001 |

AC, adenocarcinoma; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; IRB, inflammatory response biomarker; LMR, lymphocyte-to-monocyte ratio; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte; SC squamous carcinoma; SD, standard deviation; SD, standard deviation; TNM, tumor node metastasis; bold text indicates significance.

Figure 2 Kaplan–Meier survival curves showing the correlation between the inflammatory response biomarker (IRB) score and overall survival in 261 non-small cell lung cancer patients. (—) IRB score < 2, and (—) IRB score ≥ 2.

Figure 3 Kaplan–Meier survival curves showing the correlation between the inflammatory response biomarker (IRB) score and disease-free survival in 261 non-small cell lung cancer patients. (—) IRB score < 2, and (—) IRB score ≥ 2.
Table 4 Univariate and multivariate Cox regression analyses of overall survival

| Characteristics               | Univariate analysis |          |          |          |          |          |          |          |          |          |          |
|------------------------------|---------------------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|
|                              | HR (95% CI)         | P        | HR (95% CI) | P        | HR (95% CI) | P        | HR (95% CI) | P        | HR (95% CI) | P        | HR (95% CI) | P        |
| Male                         | 1.698 (1.019–2.829) | 0.042    | 0.594 (0.189–1.861) | 0.371    | 0.605 (0.202–1.812) | 0.369    |                                        |          |          |          |
| Age                          | 1.025 (0.995–1.056) | 0.098    | 1.024 (0.994–1.056) | 0.117    | 1.018 (0.989–1.049) | 0.221    |                                        |          |          |          |
| Smoking history              | 2.272 (1.370–3.768) | 0.001    | 3.021 (0.969–9.414) | 0.057    | 2.738 (0.929–8.073) | 0.068    |                                        |          |          |          |
| Hypertension                 | 1.004 (0.593–1.700) | 0.988    |                                        |          |          |          |                                        |          |          |          |
| Diabetes mellitus            | 0.862 (0.372–1.998) | 0.862    |                                        |          |          |          |                                        |          |          |          |
| COPD                         | 1.157 (0.588–2.274) | 0.673    |                                        |          |          |          |                                        |          |          |          |
| CHD                          | 1.100 (0.345–3.507) | 0.873    |                                        |          |          |          |                                        |          |          |          |
| Emphysema                    | 2.187 (1.251–3.822) | 0.006    | 1.266 (0.694–2.307) | 0.442    | 1.384 (0.764–2.505) | 0.284    |                                        |          |          |          |
| Preoperative lung function   |                     |          |                                        |          |          |          |                                        |          |          |          |
| FEV1                         | 0.873 (0.608–1.255) | 0.463    |                                        |          |          |          |                                        |          |          |          |
| FVC                          | 1.012 (0.746–1.374) | 0.939    |                                        |          |          |          |                                        |          |          |          |
| FEV1/FVC                     | 0.459 (0.075–2.807) | 0.399    |                                        |          |          |          |                                        |          |          |          |
| Tumor size                   | 1.218 (1.053–1.409) | 0.008    | 1.065 (0.911–1.245) | 0.428    | 1.063 (0.911–1.239) | 0.438    |                                        |          |          |          |
| Pathology                    | 0.914 (0.567–1.476) | 0.714    |                                        |          |          |          |                                        |          |          |          |
| Lobectomy                    | 1.275 (0.715–2.272) | 0.410    |                                        |          |          |          |                                        |          |          |          |
| TNM stage                    | 1.926 (1.482–2.503) | < 0.001  | 2.787 (1.604–4.843) | < 0.001  | 2.721 (1.597–4.637) | < 0.001  |                                        |          |          |          |
| NLR ≥ 2.12                   | 2.031 (1.236–3.338) | 0.005    | 0.849 (0.458–1.575) | 0.604    |                                        |          |          |          |
| PLR ≥ 92.9                   | 2.064 (1.234–3.451) | 0.006    | 1.417 (0.777–2.584) | 0.256    |                                        |          |          |          |
| LMR < 4.57                   | 3.067 (1.801–5.223) | < 0.001  | 1.099 (0.629–1.919) | 0.741    |                                        |          |          |          |
| IRB score ≥ 2                | 3.579 (2.052–6.241) | < 0.001  |                                        |          | 2.696 (1.506–4.826) | 0.001    |                                        |          |          |          |

†Model 1 included the neutrophil-to-lymphocyte ratio (NLR), PLR, platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) into multivariate analysis; Model 2 included the inflammatory response biomarker (IRB) score into multivariate analysis. Bold text indicates significance. AC, adenocarcinoma; CHD, coronary heart disease; CI, confidence interval; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; HR, hazard ratio; SC, squamous carcinoma; TNM, tumor node metastasis.

strategies if lung cancer prognosis could be predicted through a routine blood examination.

The association between blood cell counts or their ratios with lung cancer prognosis has been explored.22–25 Yin et al. conducted a meta-analysis including 2734 patients from 14 studies and reported that a high NLR was a predictor of poor OS in lung cancer (HR 1.192, 95% CI 1.061–1.399; \( P_{\text{heterogeneity}} = 0.003 \)).23 Zhang et al. also conducted a meta-analysis of 2889 patients from 12 studies and reported that NSCLC patients with an elevated PLR were more likely to have shorter OS after therapy (HR 1.492, 95% CI 1.231–1.807; \( P < 0.001 \)).24 Furthermore, in their meta-analysis including 3954 patients from eight studies, Li et al. demonstrated that a low LMR was significantly associated with poorer OS (HR 1.651, 95% CI 1.306–2.086, \( P < 0.001 \)) and progression-free survival (PFS, HR 1.431, 95% CI 1.294–1.582, \( P < 0.001 \)).25 However, our results indicated that none of the three ratios were independent prognostic factors for OS of NSCLC, thus a larger sample is required to verify their value for predicting NSCLC prognosis.

Although the mechanisms by which the SIR affects lung cancer prognosis are not yet clear, some significant progress has been reported. Tumor-associated neutrophils (TANs), which are derived from peripheral neutrophils, are considered key mediators in tumor progression because they can accelerate tumor growth, stimulate angiogenesis, cause genetic instability, and improve the invasiveness of tumor cells.26 Tumor-associated macrophages (TAMs), which are derived from circulating monocytic precursors, play a key role in the inflammatory microenvironment of tumor progression.26 TAMs can produce angiogenic and growth factors, as well as the protease enzyme, which promote the degradation of extracellular matrixes and induce angiogenesis, accelerate tumor cell proliferation, and favor metastasis and invasion.27 Unlike neutrophils and monocytes, lymphocytes play an essential role in the regulation of host cell-mediated immunity, which is helpful for destroying residual malignant cells and related micrometastases.28 Meanwhile, it is well known that tumor-infiltrating lymphocytes (TILs) are correlated with improved clinical outcomes in cancers.29 Recent studies have reported that platelets are important for tumor angiogenesis.30,31 The mechanism may be that platelets adhere to tumor vessels and release granules containing potent angiogenesis stimulators, such as the platelet-derived endothelial cell growth factor.30,31 All of the mechanisms we examined...
may explain why patients with a high NLR, a high PLR, or a low LMR have poor survival rates.

Most studies of the prognostic significance of SIR only focused on single factors and did not attempt to combine these biomarkers. Our study described a novel scoring system that utilized the combination of NLR, PLR, and LMR, the IRB score. The IRB was superior to the single ratios for predicting NSCLC prognosis, indicating that this measure may be more useful than these ratios alone.

Our study excluded patients who experienced a conversion from thoracoscopic surgery to thoracotomy. According to research by Oda et al., thoracoscopic surgery could reduce blood loss, the duration of chest tube placement, postoperative hospital stay and CRP level, and improve five-year OS and DFS compared to thoracotomy in early NSCLC patients.32 Their results indicate that the surgical method had a significant influence on peripheral blood inflammatory biomarkers and prognosis. Therefore, patients undergoing a change to thoracotomy were excluded from our study to decrease the bias caused by the surgical approach.

There were some limitations to our study. First, it was a retrospective study from a single center, thus the sample size was small. Second, the median follow-up was 38 (range: 1–56) months; therefore we were not able to observe the predictive effect of the IRB score on long-term prognosis. Third, we excluded patients who underwent another surgery within three months before thoracoscopic surgery because surgery can cause changes to the SIR. However, whether the interval of three months was sufficient is unclear. Four, the optimal cutoff values of the NLR, PLR, and LMR in our study were 2.12, 92.9, and 4.57, respectively. In previous studies, their critical values ranged from 2.5 to 5, 106 to 300, and 2.62 to 4.56, respectively.23–25 Therefore, the critical values in the current study may only be appropriate to the population of our center. If physicians from other medical centers attempt to apply this prognostic scoring system, we suggest that they perform their own analysis to obtain the local cutoff values that are appropriate to the specific patient population. Five, we only enrolled the NLR, PLR, and LMR into our prognostic scoring system. There are additional systemic inflammatory biomarkers with high prognostic significance, such as the prognostic nutritional index and mGPS.22,33 Unfortunately, they were not routinely available in our department. Future studies of the prognostic scoring system should include as many systemic inflammation indicators as possible. Finally, because of a lack of external data, our results could not be further validated.

In conclusion, in this study we developed a novel prognostic scoring system using the NLR, PLR, and LMR that

---

### Table 5 Univariate and multivariate Cox regression analyses of disease-free survival

| Characteristics         | Univariate analysis | Multivariate analysis |
|-------------------------|---------------------|-----------------------|
|                         | HR (95% CI)         | P         | HR (95% CI) | P         |
| Male                    | 1.622 (1.015–2.590) | **0.043** | 0.388 (0.138–1.090) | 0.072 | 0.402 (0.147–1.101) | 0.076 |
| Age                     | 1.013 (0.986–1.041) | 0.354 | 1.072 (0.644–1.786) | 0.505 | 2.938 (1.042–8.284) | **0.042** |
| Smoking history         | 2.001 (1.265–3.165) | **0.003** | 2.949 (1.086–8.026) | **0.034** |
| Hypertension            | 1.125 (0.698–1.813) | 0.629 | 1.132 (0.984–1.302) | 0.131 | 1.324 (0.220–7.948) | 0.759 |
| Diabetes mellitus       | 1.043 (0.501–2.169) | 0.910 | 1.113 (0.985–1.298) | 0.081 | 1.311 (0.985–1.298) | 0.810 |
| COPD                    | 1.221 (0.673–2.217) | 0.512 | 1.323 (0.220–7.948) | 0.759 | 1.217 (0.491–3.062) | 0.131 |
| CHD                     | 0.857 (0.270–2.719) | 0.793 | 1.131 (0.985–1.298) | 0.081 | 1.131 (0.985–1.298) | 0.081 |
| Emphysema               | 1.890 (1.125–3.176) | **0.016** | 1.598 (0.894–2.856) | 0.079 | 1.667 (0.942–2.949) | 0.079 |
| Age                     | 1.013 (0.986–1.041) | 0.354 | 1.072 (0.644–1.786) | 0.505 | 2.938 (1.042–8.284) | **0.042** |
| Smoking history         | 2.001 (1.265–3.165) | **0.003** | 2.949 (1.086–8.026) | **0.034** |
| Hypertension            | 1.125 (0.698–1.813) | 0.629 | 1.132 (0.984–1.302) | 0.131 | 1.324 (0.220–7.948) | 0.759 |
| Diabetes mellitus       | 1.043 (0.501–2.169) | 0.910 | 1.113 (0.985–1.298) | 0.081 | 1.311 (0.985–1.298) | 0.810 |
| COPD                    | 1.221 (0.673–2.217) | 0.512 | 1.323 (0.220–7.948) | 0.759 | 1.217 (0.491–3.062) | 0.131 |
| CHD                     | 0.857 (0.270–2.719) | 0.793 | 1.131 (0.985–1.298) | 0.081 | 1.131 (0.985–1.298) | 0.081 |
| Emphysema               | 1.890 (1.125–3.176) | **0.016** | 1.598 (0.894–2.856) | 0.079 | 1.667 (0.942–2.949) | 0.079 |

*Model 1 included the neutrophil-to-lymphocyte ratio (NLR), PLR, platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) into multivariate analysis; Model 2 included the inflammatory response biomarker (IRB) score into multivariate analysis. Bold text indicates significance. AC, adenocarcinoma; CHD, coronary heart disease; CI, confidence interval; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; HR, hazard ratio; SC, squamous carcinoma; TNM, tumor node metastasis.

---

Y. Wang et al. A novel scoring system in NSCLC

© 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd

Thoracic Cancer 10 (2019) 1402–1411
we termed the IRB score, and demonstrated that an IRB score $\geq 2$ was an independent prognostic factor for poor survival. Additional prospective multicenter studies are needed to confirm its prognostic significance in NSCLC.

**Disclosure**

No authors report any conflict of interest.

**References**

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. *CA Cancer J Clin* 2013; 63: 11–30.
2. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: Epidemiology, etiology, and prevention. *Clin Chest Med* 2011; 32: 605–44.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin* 2011; 61: 69–90.
4. Fan H, Shao ZY, Xiao YY et al. Incidence and survival of non-small cell lung cancer in Shanghai: A population-based cohort study. *BMJ Open* 2015 23; 5: e009419.
5. Tas F, Ciftci R, Kilic L, Karabulut S. Age is a prognostic factor affecting survival in lung cancer patients. *Oncol Lett* 2013; 6: 1507–13.
6. Wainer Z, Wright GM, Gough K et al. Impact of sex on prognostic host factors in surgical patients with lung cancer. *ANZ J Surg* 2017; 87: 1015–20.
7. Yoshino I, Maehara Y. Impact of smoking status on the biological behavior of lung cancer. *Surg Today* 2007; 37: 725–34.
8. Sobin LH, Gospodarowicz MK, Wittekind C. *TNM Classification of Malignant Tumours*, 7th edn. Wiley-Blackwell, Chichester, 2009.
9. Yoon HM, Ryu KW, Nam BH et al. Is the new seventh AJCC/UICC staging system appropriate for patients with gastric cancer? *J Am Coll Surg* 2012; 214: 88–96.
10. Gu X, Ma C, Yuan D, Song Y. Circulating soluble intercellular adhesion molecule-1 in lung cancer: A systematic review. *Transl Lung Cancer Res* 2012; 1: 36–44.
11. Tanner NT, Sherman CA, Silvestri GA. Biomarkers in the selection of maintenance therapy in non-small cell lung cancer. *Transl Lung Cancer Res* 2012; 1: 96–8.
12. Salmiheimo A, Mustonen H, Stenman UH et al. Systemic inflammatory response and elevated tumour markers predict worse survival in resectable pancreatic ductal adenocarcinoma. *PloS One* 2016 15; 11: e0163064.
13. Hirahara N, Matsubara T, Mizota Y, Ishibashi S, Tajima Y. Prognostic value of preoperative inflammatory response biomarkers in patients with esophageal cancer who undergo a curative thoracoscopic esophagectomy. *BMC Surg* 2016; 16: 66.
14. Sierzega M, Lenart M, Rutkowska M et al. Preoperative neutrophil-lymphocyte and lymphocyte–monocyte ratios reflect immune cell population rearrangement in resectable pancreatic cancer. *Ann Surg Oncol* 2017; 24: 808–15.
15. Ding N, Pang Z, Shen H, Yi N, du J, Liu Q. The prognostic value of PLR in lung cancer, a meta-analysis based on results from a large consecutive cohort. *Sci Rep* 2016; 6: 34823.
16. Templeton AJ, McNamara MG, Seruga B et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis. *J Natl Cancer Inst* 2014; 106: dju124.
17. Hu P, Shen H, Wang G, Zhang P, Liu Q, du J. Prognostic significance of systemic inflammation-based lymphocyte monocyte ratio in patients with lung cancer: Based on a large cohort study, *PLoS One* 2014; 9: e108062.
18. Gu X, Sun S, Gao XS et al. Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: Evidence from 3,430 patients. *Sci Rep* 2016; 6: 23893.
19. Stotz M, Pichler M, Absenger G et al. The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. *Br J Cancer* 2014; 110: 435–40.
20. Stotz M, Szkandera J, Stojakovic T et al. The lymphocyte to monocyte ratio in peripheral blood represents a novel prognostic marker in patients with pancreatic cancer. *Clin Chem Lab Med* 2015; 53: 499–506.
21. Lan H, Zhou L, Chi D et al. Preoperative platelet to lymphocyte and neutrophil to lymphocyte ratios are independent prognostic factors for patients undergoing lung cancer radical surgery: A single institutional cohort study. *Oncotarget* 2017; 8: 35301–10.
22. Zhu L, Chen S, Ma S, Zhang S. Glasgow prognostic score predicts prognosis of non-small cell lung cancer: A meta-analysis. *Springerplus* 2016; 5: 439.
23. Yin Y, Wang J, Wang X et al. Prognostic value of the neutrophil to lymphocyte ratio in lung cancer: A meta-analysis. *Clinics (Sao Paulo)* 2015; 70: 524–30.
24. Zheng H, Gao L, Zhang B, Zhang L, Wang C. Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: A systematic review and meta-analysis. *Sci Rep* 2016; 6: 22618.
25. Li W, Ma G, Wu Q, Deng Y, Liu Y, Wang J. Prognostic value of lymphocyte-to-monocyte ratio among Asian lung cancer patients: A systematic review and meta-analysis. *Oncotarget* 2017; 8: 110606–13.
26. Galdiero MR, Garlanda C, Jaillon S, Marone G, Mantovani A. Tumor associated macrophages and neutrophils in tumor progression. *J Cell Physiol* 2013; 228: 1404–12.
27. Balkwill F, Mantovani A. Inflammation and cancer: Back to Virchow? *Lancet* 2001; 357: 539–45.
28. Sarraf KM, Belcher E, Raevsky E et al. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. *J Thorac Cardiovasc Surg* 2009; 137: 425–8.
29. Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. *N Engl J Med* 2003; 348: 203–13.
30. Pinedo HM, Verheul HM, D’Amato RJ et al. Involvement of platelets in tumour angiogenesis? *Lancet* 1998; 352: 1775–7.
31 O’Byrne KJ, Koukourakis MI, Giatromanolaki A et al. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 2000; 82: 1427–32.
32 Oda R, Okuda K, Osaga S et al. Long-term outcomes of video-assisted thoracoscopic surgery lobectomy vs. thoracotomy lobectomy for stage IA non-small cell lung cancer. Surg Today 2019; 49: 369–77.
33 Sun K, Chen S, Xu J et al. The prognostic significance of the prognostic nutritional index in cancer: A systematic review and meta-analysis. J Cancer Res Clin Oncol 2014; 140: 1537–49.